Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
In-Depth Reviews
You have accessRestricted Access

Effect of Red Cell Transfusions on Future Kidney Transplantation

Gregorio T. Obrador and Iain C. Macdougall
CJASN May 2013, 8 (5) 852-860; DOI: https://doi.org/10.2215/CJN.00020112
Gregorio T. Obrador
*Universidad Panamericana School of Medicine, Mexico City, Mexico, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iain C. Macdougall
†Department of Renal Medicine, King’s College Hospital, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Lymphocytotoxic antibody reactivity against random donor test panel in relation to the number of blood transfusions. Fractions of patients reacting against <10%, 10%–50%, 51%–90%, and >90% of the panel donors are plotted. All 737 patients were undergoing long-term hemodialysis and were waiting for a first kidney transplant. Numbers of patients after 2, 5, 10, 15, and 20 transfusions are indicated at top of graphs. (A) Male and female patients. (B) Female patients categorized by the number of previous pregnancies. (C) Lymphocytotoxic antibodies in patients who were studied prospectively throughout the course of treatment (32).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Effect of pretransplant transfusion on the risk of elevated panel-reactive antibody in transplant patients, by sex, 2004–2008 (24). PRA, panel-reactive antibody. Error bars are 95% confidence intervals. Reproduced from reference 24.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Clinical algorithm to guide the use of red cell transfusions in patients with CKD. ESA, erythropoiesis-stimulating agent.

Tables

  • Figures
    • View popup
    Table 1.

    Indications for Blood Transfusions

    IndicationComments
    When rapid correction of anemia is required to stabilize the patient’s condition (e.g., acute hemorrhage, unstable coronary artery disease)Red cell transfusion in patients with acute hemorrhage is indicated when there is: (1) rapid acute hemorrhage without immediate control; (2) estimated blood loss of >30%–40% (1500–2000 ml) with symptoms of severe blood loss; and (3) estimated blood loss <25%–30% with no evidence of uncontrolled hemorrhage if there are recurrent signs of hypovolemia despite colloid/crystalloid resuscitation. In patients with certain comorbid factors, transfusions may be necessary with less blood loss (69).
    Studies evaluating the importance of anemia and the role of transfusion in the setting of an acute coronary syndrome (i.e., unstable angina, myocardial infarction) have reached differing conclusions.
    The American College of Cardiology/American Heart Association and American College of Chest Physicians guidelines did not make any recommendations concerning the potential benefit or risk of blood transfusion in the setting of an acute coronary syndrome (70,71).
    Although anemia occurs frequently in patients with heart failure, limited data are available on treatment of anemia in this population.
    Correction of anemia has not been established as a routine treatment in heart failure, as noted in the 2005 American College of Cardiology/American Heart Association guidelines, the 2006 Heart Failure Society of America guidelines, and the 2008 European Society of Cardiology guidelines (72–74).
    General indications for red cell transfusion may be applied to patients with acute coronary syndrome and/or heart failure; however, careful attention to volume status is indicated when there is coexistent renal impairment.
    When rapid preoperative hemoglobin correction is requiredCriteria have been proposed for the administration of perioperative transfusions, as follows (69):
     Red cell transfusions are generally not recommended when hemoglobin level is ≥10 g/dl in otherwise healthy person.
     Red cell transfusions should be given when hemoglobin level is <7 g/dl.
     When hemoglobin level is <7 g/dl and the patient is otherwise stable, 2 units of packed red cells should be transfused, following which the patient's clinical status and circulating hemoglobin should be reassessed.
     High-risk patients (those age >65 years or those with cardiovascular or respiratory disease) may tolerate anemia poorly and may be transfused when hemoglobin level is <8 g/dl.
     For hemoglobin level 7–10 g/dl, the correct strategy is unclear.
    When symptoms and signs related to anemia are present in patients in whom ESA therapy is ineffective (e.g., those with bone marrow failure, hemoglobinopathies, ESA resistance)Patients with chronic anemia (e.g., those with bone marrow failure syndromes or hemoglobinopathies) may be dependent on red cell replacement over a period of months or years, which can lead to iron overload.
    Approximately 200 mg of iron are delivered per unit of red cell; this iron is released when hemoglobin from the transfused red cell is recycled after red cell death.
    Given the progressive loss of red cell viability that occurs during storage, the “freshest available” units should be selected to maximize post-transfusion survival
    Hemosiderosis can produce organ damage when the total iron delivered approaches 15–20 g, the amount of iron present in 75–100 units of red cells, as occurs in conditions such as thalassemia or sickle cell disease.
    The issue of red cell transfusion in patients with congenital or acquired hemolytic anemia is more complex.
    When symptoms and signs related to anemia are present in patients in whom the risks of ESA therapy may outweigh the benefitsESAs should be used with great caution, if at all, in patients with CKD with active malignancy, a history of malignancy, or a history of stroke.
    • ESA, erythropoiesis-stimulating agent.

PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 8 (5)
Clinical Journal of the American Society of Nephrology
Vol. 8, Issue 5
May 07, 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Effect of Red Cell Transfusions on Future Kidney Transplantation
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effect of Red Cell Transfusions on Future Kidney Transplantation
Gregorio T. Obrador, Iain C. Macdougall
CJASN May 2013, 8 (5) 852-860; DOI: 10.2215/CJN.00020112

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Effect of Red Cell Transfusions on Future Kidney Transplantation
Gregorio T. Obrador, Iain C. Macdougall
CJASN May 2013, 8 (5) 852-860; DOI: 10.2215/CJN.00020112
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Summary
    • Introduction
    • Overview of Blood Transfusion Use in Patients with CKD
    • Evidence for Blood Transfusions Causing Increased HLA Sensitization
    • Effect of Leukocyte Depletion on Risk of HLA Sensitization after Blood Transfusion
    • Effect of Increased HLA Sensitization on Waiting Time for Transplantation
    • Effect of HLA Sensitization on Outcomes after Renal Transplantation
    • Conclusions and Recommendations
    • Disclosures
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Assessing Physical Function and Physical Activity in Patients with CKD
  • Management of Crush Victims in Mass Disasters: Highlights from Recently Published Recommendations
Show more In-Depth Reviews

Cited By...

  • Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire